Clinical trials: Intravenous Immunoglobulin
Autoimmune Autonomic Ganglionopathy (AAG)
Evaluating the Effectiveness of Intravenous Immunoglobulin Therapy in Autoimmune Autonomic Ganglionopathy
The purpose of the study is to see if administering intravenous immune globulin (IVIG) (putting immune globulin directly into your blood) helps to improve the symptoms of orthostatic hypotension (sudden fall in blood pressure…
- Trial name
- NCT01522235
- Testing
- Double blinded IVIg, Single Blinded IVIg
- Where
- 6 sites in United States
- Volunteers
- 6 people
- Sponsor
- Beth Israel Deaconess Medical Center
Kawasaki Disease Refractory to Initial Therapy With Intravenous Immunoglobulin
Clinical Study of TA-650 in Patients With Refractory Kawasaki Disease
The purpose of this study is to evaluate the efficacy and safety of TA-650 in comparison with a control drug Polyethylene Glycol-treated Human Immunoglobulin (VGIH) in patients with Kawasaki disease refractory to initial therapy…
- Trial name
- NCT01596335
- Testing
- TA-650, Polyethylene Glycol-treated Human Immunoglobulin (VGIH)
- Where
- 8 sites in Japan
- Volunteers
- 31 people
- Sponsor
- Tanabe Pharma Corporation
Polyneuropathies
The Impact of IVIG Treatment on Critical Illness Polyneuropathy and/or Myopathy in Patients With MOF and SIRS/Sepsis
Critical illness polyneuropathy and/or myopathy (CIPNM) is a severe complication of critical illness. Retrospective data suggest that early application of IgM-enriched intravenous immunoglobulin (IVIG) may prevent or mitigate…
- Trial name
- CIPNM (NCT01867645)
- Testing
- IgM-enriched Intravenous Immunoglobulins, Human Albumin
- Where
- Austria
- Volunteers
- 38 people
- Sponsor
- Medical University of Vienna
Primary Immunodeficiency Disease (PIDD)
Monitoring of 5% Treatment Naïve Intravenous Immunoglobulin (IVIg) Primary Immunodeficiency Disease (PIDD) Patients Using the CareExchange® System: A Pilot Study Using 5% Gammaplex® IVIg in the Home Setting
The purpose of this study is to demonstrate the utility of measuring outcomes in 5% treatment naïve Intravenous Immunoglobulin (IVIg) Primary Immunodeficiency Disease (PIDD) patients using infusion nurse and patient measured…
- Trial name
- NCT02176239
- Where
- 4 sites in United States
- Volunteers
- 20 people
- Sponsor
- BriovaRx Infusion Services
Rheumatoid Arthritis
Safety and Efficacy of Intravenous ACZ885 and Oral Methotrexate Therapy in Patients With Early Rheumatoid Arthritis
This study was intended to evaluate the safety and efficacy of intravenous (IV) ACZ885 and oral methotrexate (MTX) therapy in patients with early rheumatoid arthritis (RA)
- Trial name
- NCT00487825
- Testing
- Canakinumab (investigational), Methotrexate (MTX)
- Where
- 22 sites in United States, Belgium and 4 more
- Volunteers
- 78 people
- Sponsor
- Novartis
Haemolysis Neonatal
Efficacy of Intravenous Immunoglobulin in Management of Rh and ABO Incompatibility Disease
hemolytic disease of newborn is an important cause of hyperbilirubinemia with significant morbidity and mortality in neonatal period. intravenous immunoglobulin has widely used in management of hemolytic disease of new born
- Trial name
- IVIG (NCT03130517)
- Testing
- intravenous immunoglobulin
- Volunteers
- 30 people
- Sponsor
- Assiut University
Clostridium Difficile-associated Diarrhea (CDAD)
IVIG Versus Placebo for the Treatment of Patients With Severe C-Diff
In this trial, eligible patients will be randomly assigned to receive a single dose of 400 mg/kg of IVIG or a normal saline infusion as placebo over 4-6 hours, in addition to their usual medications for CDAD.
- Trial name
- NCT00177970
- Testing
- intravenous immunoglobulin G (IVIG)
- Where
- 4 sites in United States
- Volunteers
- 14 people
- Sponsor
- University of Pittsburgh
COVID-19 Infection
A Study on the Effects in Healthy People of a New Drug Called PDI204 for Treating COVID-19
The goal of this clinical trial is to learn if a new drug called PDI204, developed for treating or preventing COVID-19, is safe and well-tolerated in healthy volunteers. This is a first-in-human study.
- Trial name
- PHONIC (NCT06965751)
- Testing
- PDI204, 0.9 % saline
- Where
- Australia
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- University of Melbourne
Rhesus Negative Pregnant Women
Routine Fetal RhD Genotyping for RhD- Pregnant Women
The study is divided in two sub-studies. The first one is an economical and performance comparison between two antenatal management strategies of RhD negative pregnant women: the first one will comprise non invasive RhD fetal…
- Trial name
- GENIFERH (NCT00832962)
- Testing
- Genotyping, Usual prophylaxis
- Where
- France
- Volunteers
- 2,532 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
Immune Globulin Intravenous (IGIV) For Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
The intent of this study is to demonstrate the efficacy and safety of Immune Globulin Intravenous (Human), 10% Caprylate/Chromatography Purified (IGIV-C) in newly or previously diagnosed CIDP subjects.
- Trial name
- ICE (NCT00220740)
- Testing
- Immune Globulin IV (Human), 10% Caprylate/Chromatography Purified, Albumin (Human) 25%, United States Pharmacopeia (USP)
- Where
- 32 sites in United States, Argentina and 8 more
- Volunteers
- 117 people
- Sponsor
- Grifols Therapeutics LLC
Diffuse Cutaneous Systemic Sclerosis
Efficacy and Safety of IgPro10 in Adults With Systemic Sclerosis (SSc)
This randomized, multicenter, double-blind (DB), placebo controlled, phase 2 study will evaluate the efficacy and safety of IgPro10. The DB Treatment Period will be followed by a 24-week Open-label (OL) Treatment Period.
- Trial name
- NCT04138485
- Testing
- IgPro10
- Where
- 77 sites in United States, Argentina and 11 more
- Sponsor
- CSL Behring
Hematological Malignancy
Phase 1/2 Dose Escalation and Efficacy Study of Anti-CD38 Monoclonal Antibody in Patients With Selected CD38+ Hematological Malignancies
Primary Objective: Phase 1: To determine the maximum tolerated dose (MTD)/maximum administered dose (MAD) of SAR650984 (Isatuximab).
- Trial name
- NCT01084252
- Testing
- Isatuximab SAR650984, Dexamethasone
- Where
- 59 sites in United States, Argentina and 15 more
- Volunteers
- 351 people, healthy volunteers welcome
- Sponsor
- Sanofi
Healthy Volunteers
A Study of TAK-881 in Healthy Adults
The main aims of this study are to check for side effects from TAK-881 in healthy adults and to learn how much TAK-881 they can receive without getting side effects from it.
- Trial name
- NCT05059977
- Testing
- TAK-881
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Takeda
NMOSD
Efficacy and Safety of Monoclonal Antibody in Acute Phase of Neuromyelitis Optica Spectrum Disorder
This study aims to evaluate the efficacy and safety of different monoclonal antibody in the acute phase of neuromyelitis optica spectrum disorder (MAAP-NMO).
- Trial name
- NCT07182409
- Volunteers
- 40 people
- Sponsor
- First Affiliated Hospital of Chongqing Medical University
Covid19, Pneumonia
Intravenous Immunoglobulin (IVIG, Bioven) Efficacy Assess for COVID-19 / SARS-CoV-2 Severe Pneumonia Complex Treatment
Pneumonia caused by coronavirus infection COVID-19 is characterized by a combination of several dangerous factors that consistently worsen the patient's condition: viral lung damage early in the disease; a sharp increase in…
- Trial name
- NCT04500067
- Testing
- IVIG
- Where
- 9 sites in Ukraine
- Volunteers
- 76 people
- Sponsor
- Biopharma Plasma LLC
Chronic Inflammatory Demyelinating Polyradiculoneuropathy
A Study of HyQvia and Gammagard Liquid (Kiovig) in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
The aim of this study is to learn more about the following treatment options in adults with CIDP: Subcutaneous self-infusion with HyQvia. Intravenous infusion with Gammagard/Kiovig.
- Trial name
- NCT02549170
- Testing
- HYQVIA, IGIV GAMMAGARD LIQUID/KIOVIG, IGIV GAMUNEX®-C
- Where
- 83 sites in United States, Argentina and 20 more
- Volunteers
- 138 people
- Sponsor
- Baxalta now part of Shire
Pain, Acute, Alloimmunisation in Pregnancy
Efficacy of Manuel Pressure and Local Cold Spray in Reducing Injection Pain in Pregnant Women
A randomized controlled study was planned to determine the effect of manual pressure and local cold spray application on the intensity of pain, fear, hemodynamic parameters, and satisfaction related to the pain reduction of human…
- Conditions
- Pain, Acute, Alloimmunisation in Pregnancy, Injection Site, Injection Fear
- Trial name
- NCT06231719
- Testing
- Cold Spray, Manuel Pressure, Standard Injection Procedure
- Where
- Turkey (Türkiye)
- Volunteers
- 129 people, healthy volunteers welcome
- Sponsor
- Gulsum Coskun
Primary Immunodeficiency Disease
Study to Investigate Efficacy, Safety and Pharmacokinetics of BT595 in Subjects With PID
This Phase III clinical study is to test efficacy, safety and pharmacokinetics of BT595 in treating patients with Primary Immunodeficiency (PID)
- Trial name
- NCT02810444
- Testing
- IgG Next Generation (BT595)
- Where
- 19 sites in United States, Germany and 3 more
- Volunteers
- 81 people
- Sponsor
- Biotest
Thrombocytopenia, Neonatal Alloimmune
A Study of Nipocalimab or Intravenous Immunoglobulin (IVIG) in Pregnancies At Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)
The purpose of this study is to assess the efficacy and safety of nipocalimab in reducing the risk of severe fetal and neonatal alloimmune thrombocytopenia (FNAIT).
- Trial name
- FREESIA-3 (NCT06533098)
- Testing
- Nipocalimab, Intravenous immunoglobulins (IVIG), Prednisone
- Where
- 28 sites in United States, Austria and 5 more
- Volunteers
- 50 people
- Sponsor
- Janssen Research & Development, LLC
Immune Thrombocytopenic Purpura (ITP)
Safety and Tolerability of M254 in Healthy Volunteers and Immune Thrombocytopenic Purpura (ITP) Patients
The purpose of this study is to assess safety, tolerability, pharmacokinetics, and pharmacodynamics of M254 after administration of a single ascending dose and repeat doses in healthy volunteers and immune thrombocytopenic…
- Trial name
- NCT03866577
- Testing
- Biological: M254, Intravenous immunoglobulin (IVIg)
- Where
- 28 sites in United States, Belgium and 5 more
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Momenta Pharmaceuticals, Inc.